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Aims:We sought to establish the responsiveness of the Dutch Vancouver Symptom
Score for Dysfunctional Elimination Syndrome (VSSDES) and Pediatric urinary
incontinence Quality of life (PinQ) questionnaires. Secondary, we evaluated the
outcome of urotherapy extended for children with dysfunctional voiding (DV).
Methods: This cross-sectional multicenter study was done in one tertiary and two
community hospitals. Children with DV were included, also when refractory to
previous urotherapeutic treatment. The questionnaires were completed before and
after urotherapy. The primary outcome measure was the responsiveness of the Dutch
VSDESS and PinQ. Secondary outcome was the initial success (defined by the
International Children's Continence Society) of extended urotherapy.
Results: Between June 2014 and May 2016, 64 children (median age 7 years, IQR
6-10) received urotherapy (median 18 weeks, IQR 11-28). In contrast to the VSSDES,
the PinQ showed good responsiveness. For children and parents, respectively, the area
under the ROC-curve was 0.79 (P= 0.01) and 0.72 (P= 0.03) for the PinQ and 0.50
(P= 0.98) and 0.55 (P= 0.62) for the VSSDES. Fifty children received extended
urotherapy, 27 had complete, and 14 had partial response. Sixteen children had been
refractory to previous treatment; four showedcomplete, and six showedpartial response.
Conclusion: The PinQ is able to detect clinically important changes in continence-
specific quality of life after treatment. We support the use of the VSSDES
questionnaire in addition to the current diagnostics for the diagnosis of DV. Extended
urotherapy showed to be a successful treatment for children with DV, also for those
who had received previous unsuccessful treatment.
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1 | INTRODUCTION
Lower urinary tract symptoms (LUTS) are a common
reason for children to visit the pediatrician or pediatric
urologist.1–3 Symptoms related to the voiding and storage
phase of bladder can contribute to numerous functional
elimination disorders.3,4 Dysfunctional voiding (DV) is a
common cause of LUTS in neurologically intact children.4
Voiding symptoms such as straining, hesitancy, dysuria,
and storage symptoms such as frequency, urgency, or
incontinence are suggestive for DV.3–5 Furthermore, DV is
often associated with recurrent urinary infections, and
bowel dysfunction such as constipation or fecal inconti-
nence.5,6 The symptoms of DV can have a negative impact
on a child's quality of life and self-esteem.1,2,6 The
International Children's Continence Society (ICCS) has
defined DV as habitual contractions of the urethral sphincter
or pelvic floor during voiding. The uroflowmetry curve
demonstrates a staccato pattern with or without an
interrupted flow concomitant with activity on EMG.4,5
The exact epidemiology of DV is unknown.5 The preva-
lence of DV in the general population has a wide range: 4.2-
46.4%.5,6
Urotherapy and pelvic muscle floor retraining can be a
successful treatment in the majority of these children.3,6
Urotherapy is a non-standardized conservative based treat-
ment option for children with voiding dysfunctions.4,5
According to the ICCS, urotherapy includes education about
lower urinary tract anatomy and function, as well as life-style
advices (balanced fluid intake, diet, proper voiding posture
without holding maneuvers, regular bladder, and bowel
emptying patterns).4,5 During follow up the child will be
encouraged to comply with therapy and the LUTS will be
monitored by bladder, bowel, and intake diary.4,5 Urotherapy
can be extended with visual biofeedback by two approaches:
feedback of the uroflow curve and teaching perineal muscle
identification by EMG electrodes.1,3,5,6 The physical therapist
can extend the urotherapy with pelvic floor muscle retraining,
which implies learning how to relax the pelvic floor during
voiding.1,3–6
Administering a condition-specific questionnaire can be
useful to evaluate LUTS and effect of the treatment.
Subjective complaints can be translated objectively into a
total score.4 Two English-language questionnaires were
translated into Dutch and proved to have good validity and
reliability. One is the Pediatric urinary incontinence Quality
of life score (PinQ), which measures the continence-specific
quality of life in children with bladder dysfunction.7,8 The
other is the Vancouver Symptom Score for Dysfunctional
Elimination Syndrome (VSSDES), which evaluates the
symptoms of patients with DV.9
In the study presented here we followed children with DV
during their treatment. Our primary aim of this study was to
evaluate the responsiveness of the Dutch-language versions
of the VSSDES and PinQ. Secondary, we evaluated the
results of extended urotherapy.
2 | MATERIALS AND METHODS
2.1 | Study design and population
The local ethics committee approved this multicenter
prospective cross-sectional study (MEC-2014-290). Children
with the age between 4 and 17 years presenting with DV at the
pediatric, pediatric urology, or pelvic floor physical therapy
outpatient clinics at two community hospitals and one tertiary
hospital in the Netherlands between June 2014 and May 2016
were eligible for inclusion in the study. Children who had a
previous unsuccessful treatment in a different setting were
included as well. Patients with a neurogenic disease, anatomic
abnormalities of the urinary tract, and previous urological
surgery were excluded. The diagnosis DV was based on
clinical symptoms, and a staccato and/or intermittent
uroflowmetry with increased activity on pelvic floor EMG.
After signing informed consent, patients, and parents were
asked to fill out the questionnaires twice: after inclusion and
after finishing urotherapy.
2.2 | Questionnaires
Prior to urotherapy, patients, and parents filled out the
VSSDES and the PinQ. The VSSDES is a 14-item condition-
specific measure to evaluate the symptoms of bladder and
bowel dysfunction. The last question addresses the ease with
which the questionnaire can be completed, and the response to
this question is excluded from the total score. Responses are
given on a 5-point Likert scale, ranging from zero (no
complaints) to four (severe symptoms) except for question 3
about voiding frequency (5-6 times: score of 0; 3-4 times or 7-
8 times: score of 2; 1-2 times or >8: score of 4). All items are
weighted equally. A total score is obtained by summating the
item scores; the higher the total score the more severe the
symptoms.10 A cutoff score of 11 is established for the Dutch
version.9
The PinQ is a 20-item questionnaire to evaluate the
quality of life of children with urinary incontinence. All items
are scored on a 5-point Likert scale. A higher total score
corresponds with a lower quality of life.8 Incompletely filled
out questionnaires were accepted if no more than two answers
were missing. Then the total score is calculated by
multiplying the number of items in the questionnaire by the
mean value of responses to the answered questions. No cutoff
score is published for the PinQ. Thibodeau et al2 made an
assumption to grade the severity of impact on quality of life:
mild <20, moderate 21-50, and severe >51.
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After urotherapy had finished, patients, and parents again
filled out the VSSDES and the PinQ and answered an
additional question derived from the RAND-36-Item Health
Survey (RAND 36-HTI): “How is your voiding problem
compared to one year ago?” (response categories: much
better, somewhat better, about the same, somewhat worse,
much worse).11
2.3 | Outcome measure questionnaires
The primary outcome measure of this study was the
responsiveness of the two questionnaire's. A questionnaire's
responsiveness is its ability to detect clinically important
changes over time in patients when treatment is given. A
measure of the responsiveness is the area under the receiver
operating characteristic (ROC) curve (AUC), according to an
external criterion. The answer to the question derived from
the RAND 36-HTI and the initial outcome served as external
criteria. The AUC shows the ability of a questionnaire to
discriminate between improvement and no improvement. An
AUC of at least 0.7 was considered to reflect adequate
responsiveness.12
2.4 | Urotherapy
Our secondary objective was to evaluate the outcome of
“extended” urotherapy. All included children received
“standard” urotherapy consisting of initial evaluation,
education, and management as described by the ICCS.4
Standard urotherapy with visual biofeedback by uroflowme-
try and EMG electrodes and/or retraining of the pelvic floor
was defined as “extended” urotherapy.
In one of the community hospitals only standard
urotherapy was given. Children visited the pediatrician
combined with a trained nurse once or twice. When standard
urotherapy failed children returned to the outpatient clinic of
the pediatrician for additional treatment with medication or
were referred to a physical therapist.
Children included in the tertiary hospital and in the other
community hospital received extended urotherapy given by a
trained nurse or physical therapist. Those children had
approximately 5-7 sessions in 4 months. During this period
the children were discussed 2-3 times with the pediatrician or
pediatric urologist. When additional treatment with anticho-
linergics was needed because of persistent urgency with
acceptable post void residual urine, the pediatrician or
pediatric urologist started tolterodine (slow release) 2 mg 1
daily, or solifenacine 5 mg 1 daily, or oxybutynine 0.4 mg/kg
3 daily for 4-12 weeks. The use of anticholinergics was re-
evaluated with the pediatrician or pediatric urologist during
urotherapy. After approximately 4 months urotherapy was
finished. When extended urotherapy failed an invasive
treatment as botulinum toxin A injections into the bladder
wall or into the urethral sphincter could be considered.
Injections in the urethral sphincter were given when an
increased activity of pelvic floor muscles or external urethral
sphincter was seen during voiding on urodynamic study. A
total of 100 IU of botulinum toxin A was injected in equal
dose into the external sphincter at the 3, 9, and 12 o’clock
positions under general anesthesia and antibiotic prophylaxis.
For boys a cystoscope was used. The transurethral approach
to the sphincter is more difficult for girls, therefore, injections
were placed paraurethral.13 In cases of persisted symptoms of
an overactive bladder without post void residual urine
botulinum toxin A injections (total dose of 70 UI) into the
bladder wall were given under general anesthesia and
antibiotic prophylaxis by cystoscopy.
2.5 | Outcome measures extended urotherapy
The outcome of extended urotherapy was defined by the
definition of initial success proposed by the ICCS: no
response (<50% reduction of LUTS), partial response (50% to
99% reduction of LUTS), and complete response (100%
reduction of LUTS).4 The children who received only
standard urotherapy were excluded in this evaluation. The
initial success and symptoms were evaluated after the last
visit of urotherapy. The initial success and effect on
symptoms of an invasive treatment (botulinum toxin A
injections) were not evaluated. Data such as symptoms, post
void residual, urinary frequency, maximum voided volume,
and fluid intake before urotherapy and at the last visit of
urotherapy were retrospectively collected. The maximum
voided volumewas retrieved from the voiding chart and refers
to the largest volume voided, excluding the first morning
void. The maximum voided volume was considered small or
large if <65% or >150% of expected bladder capacity (EBC),
respectively.4 The EBCwas defined by the formula (30× [age
in years + 1]mL).4 The maximum level was 390 mL at
12 years.4
2.6 | Statistical analysis
Statistical analyses were performed using SPSS version 21.0
(IBM Corp., Armonk, NY). A two-sided P-value <0.05 was
considered significant. Descriptive statistics were calculated
and are presented as median (interquartile range [IQR]),
frequency and percentiles. To evaluate differences in
symptoms and results of the two questionnaires between
before and after treatment, the paired-samples t-test and the
McNemar test were used for continuous and categorical
variables, respectively. One-way analysis of variance
(ANOVA) was used for the evaluation of more than two
independent groups. The answer on the RAND 36-HTI
question was dichotomized to “not improved” (including
“about the same,” “somewhat worse,” and “muchworse”) and
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“improved” (including “much better” and “somewhat
better”). The AUC was calculated to determine the
responsiveness.12
3 | RESULTS
The study population consisted of 64 children with
dysfunctional voiding and their parents. Fifty children
received extended urotherapy with or without pelvic floor
retraining. The fourteen children who received standard
urotherapy where only included to evaluate the responsive-
ness of the questionnaires. Patient characteristics are
displayed in Table 1.
3.1 | Questionnaires
The VSSDES questionnaire was completed before and after
urotherapy by 50 (78%) children and 49 (77%) parents; the
PinQ by 45 (70%) children, and 48 (75%) parents. Table 2
presents the mean difference scores (SD).
The responsiveness of the VSSEDS was measured by the
AUC calculated with the RAND-36-HTI as an external
criterion; the AUC was 0.50 (P= 0.98) for children, and 0.55
(P= 0.62) for parents. The AUC for the PinQ was 0.79
(P= 0.01) for the children and 0.72 (P= 0.03) for the parents
(Table 3).
3.2 | Outcome of extended urotherapy
Fifty children received extended urotherapy with or
without pelvic floor retraining (Table 1). Sixteen children
were refractory to previous urotherapeutic treatment and
received urotherapeutic treatment in a different setting for
the second time. Fourteen of them had received previous
urotherapeutic treatment in combination with pelvic floor
physical therapy and two had received group urotherapy.
The median duration of urotherapy was 18 weeks (IQR
11-25 weeks).
After extended urotherapy symptoms such as daytime
and nighttime incontinence, urge, dysuria, and abdominal
pain all had improved significantly (Table 4). During
urotherapy anticholinergics were prescribed to fourteen
children. After urotherapy, 64% of the children had stopped
the anticholinergics. Before treatment three girls
TABLE 2 Total mean score (SD) of the VSSDES or PinQ
questionnaire before and after urotherapy and the difference between
Total score
of the
questionnaire
Before
urotherapy
After
urotherapy Difference P-value
VSSDESb
Child n= 50
Parent n= 49
17.9 ± 6.9
17.9 ± 6.5
11.6 ± 5.9
11.5 ± 6.2
−6.3 ± 6.7
−6.4 ± 6.6
<0.001a
<0.001a
PinQc
Child n= 45
Parent n= 48
23.7 ± 14.8
21.5 ± 11.2
17.0 ± 15.0
17.1 ± 12.9
−6.7± 10.9
−4.4±12.0
<0.001a
0.015a
aPaired t-test.
bA higher total score indicates more severe symptoms.
cA higher total score indicates a lower quality-of-life.
TABLE 3 The VSSDES and PinQ scores (SD) and their
corresponding RAND-36-HTI response reflect the responsiveness
VSSDES Number (%) Mean± SDa
RAND-36-HTI n= 50
•Much better/ a little better
•Same
•Much worse/a little worse
Area under the ROC curve
P-value
41 (82.0)
7 (14.0)
2 (4.0)
−6.3 ± 7.0
−6.5 ± 5.9
−5.5 ± 2.1
0.50
0.98
Parent RAND-36-HTI n= 49
•Much better/a little better
•Same
•Much worse/a little worse
Area under the ROC curve
P-value
38 (77.5)
9 (18.4)
2 (4.1)
−6.8 ± 6.3
−6.8 ± 8.0
2.0 ± 1.4
0.55
0.62
PinQ Number (%) Mean± SDb
RAND-36-HTI n= 45
•Much better/a little better
•Same
•Much worse/a little worse
Area under the ROC curve
P-value
37 (82.2)
6 (13.3)
2 (4.5)
−8.3 ± 11.2
−0.9 ± 4.3
5.5 ± 7.8
0.79
0.01
Parent RAND-36-HTI n= 48
•Much better/a little better
•Same
•Much worse/a little worse
Area under the ROC curve
P-value
37 (77.1)
9 (18.8)
2 (4.1)
−6.7 ± 11.0
1.1 ± 12.4
14.5 ± 5.0
0.72
0.03
The RAND-36-HTI functions as an external criterion.
aA higher total score indicates more severe symptoms.
bA higher total score indicates a lower quality-of-life.
TABLE 1 Patient characteristics of the study population presented as
number (%) or median (interquartile range)
Study population n= 64
Age, median (IQR) 7 (6-10)
Number of girls, n (%) 35 (55)
Duration of the treatment in weeks, median (IQR) 18 (11-28)
Type of urotherapy, n (%)
•Standard urotherapy
•Extended urotherapy
14 (22)
50 (78)
Extended urotherapy n= 50
Age, median (IQR) 8 (7-10)
Number of girls, n (%) 28 (56)
Duration of the treatment in weeks, median (IQR) 18 (11-25)
Anticholinergics during urotherapy, n (%) 14 (28)
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experienced urinary tract infections (UTIs) with fever (≥2
in 6 months) and nine girls and one boy had UTIs without
fever (frequency: 1-3 UTIs in 12 months, five girls
unknown). During therapy, none of the children experi-
enced UTIs. The mean fluid intake increased from 985 to
1547 mL (P< 0.001, n = 43). A voiding chart was
completed at the last visit of urotherapy in 34 children.
Nineteen out of 34 children had a maximum voided volume
<65% or >150% of the EBC before therapy, 14 children
showed improvement after treatment. At the last visit of
urotherapy 37 children had undergone an uroflowmetry,
which in 12 (32.4%) of them showed a persistent staccato,
and/or intermittent flow pattern. In 7 of those 12 children
also with increased activity on pelvic floor EMG. The mean
post void residual of these 37 children decreased from 28.1
to 12.8 mL (P= 0.025).
Based on the definition initial success by the ICCS, the
treatment outcome of extended urotherapy could be
classified as complete response in 27 (54%), partial response
in 14 (28%), and no response in 9 (18%) children (Table 5).
There was a significance difference in urotherapy outcome
between the children refractory to previous urotherapeutic
treatment and those who received urotherapeutic treatment
for the first time, in disadvantage of the children refractory
to previous urotherapeutic treatment (P= 0.014). Overall,
nine out of 50 children had no response to extended
urotherapy. Three children and their parents decided to
accept the situation. Six children received botulinum toxin A
injections in the urethral sphincter (n= 4), or in the bladder
wall (n= 1), or in the urethral sphincter and bladder wall
(n= 1).
4 | DISCUSSION
The evaluation of the responsiveness of the VSSDES and
PinQ, and of patient outcomes suggest that the PinQ
questionnaire can detect clinically important changes over
time (Table 3) and that symptoms had improved after
extended urotherapy (Table 4).
The reliability and validity of the original and Dutch
versions of both questionnaireswere found to be good in earlier
studies.7–10 Completing the questionnaires makes the symp-
toms and feelings transparent and negotiable with the health
professional and family-members. This could lead to increased
empathy, support, and treatment compliance.Both,Afshar et al
and Bower et al, suggest to measure the responsiveness of the
questionnaires.7,10 As far as we know, this is the first study that
reports on the responsiveness of the questionnaires. We
hypothesized that lower post-treatment scores on the PinQ and
the VSSDES compared to the baseline scores would reflect
improvements on quality of life and symptoms. According to
the external criterion, the RAND-36-HTI question: “How is
your voiding problem compared to one year ago?” the AUC
wasmeasured. The responsiveness of both the child and parent
versions of the PinQproved to bemore than adequate, theAUC
was both above >0.7. This was not the case for the VSSDES.
Perhaps the RAND-36-HTI question solely addresses the
aspect of the voiding dysfunction and does not fully encompass
the symptoms. Besides, only two parents and children found
the voiding dysfunction to be worse now. We noted that
completing the post-treatment questionnaireswas not a priority
for the parents and children. Resulting in a median interval of
14 weeks (IQR 0-48) between ending urotherapy and
completing the last questionnaires.
In this study, theDutchVSSDES showed to be not useful to
detect clinical important changes over time in symptoms after
therapy. Still, the questionnaire is a reliable and valid tool to
more objectively and systematically evaluate symptoms of
patients with DV.9 Our hypothesis for the PinQ could be
confirmed. The children and parents who answered the
RAND-36-HTI question with “much” or “somewhat better”
had mean lower scores on the PinQ after treatment.
The children in our study showed a good initial success rate
after extended urotherapy with visual biofeedback by
TABLE 5 Initial success following the three ICCS basics principles
of treatment outcomes presented as number (%)
TABLE 4 Symptoms before and after urotherapy presented as
number (%)
Symptoms n= 50a
Before
urotherapy
n (%)
After
urotherapy
n (%) P-value
Daytime incontinence
Partial success (50-99%)
No success (<50%)
Dry
42 (84.0)
8 (16.0)
23 (46.0)
12 (24.0)
11 (22.0)
27 (54.0)
<0.001b
Nighttime incontinence
Partial success (50-99%)
No success (<50%)
Dry
30 (60.0)
20 (40.0)
16 (32.0)
3 (6.0)
13 (26.0)
34 (68.0)
<0.001b
Urge (n= 43) 21 (48.8) 6 (14.0) <0.001b
Dysuria 3 (6.0) 0
Abdominal pain 10 (20.0) 2 (4.0) 0.008b
aUnless stated otherwise.
bMcNemar test.
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uroflowmetry and EMG electrodes and/or pelvic floor
retraining. Judged from three ICCS basic principles of
treatment outcomes, extended urotherapy was successful for
82% (complete response 54%) of the children overall. The
success of treatment in children who were refractory to
previous urotherapy was 63% (complete response 25%).
Children who did not respond to previous urotherapy may be
more motivated in new and different setting. It is also possible
that themoment and the intensity of attention by the healthcare
professional or parent is relevant to success. Previous studies
have reported success rates of 90-100% of urotherapy with the
possibility to extendwith biofeedback or pelvic floor retraining
or medication (commonly an antimuscarinic) in children with
DV.5,14 Tugtepe et al15 reported on 28 children with DV
refractory to three months of standard urotherapy. All children
received additional extended urotherapy resulting in 50-100%
decrease of LUTS. The outcome of the present study is
comparable or slightly less favorable than that of these
previous studies, to which the multicenter design and the
inclusion of 16 children refractory to a previous treatment may
have contributed. Note, however, outcomes of urotherapy are
hard to compare between studies with different study
populations, treatment approaches, and definitions of success
of DV. In our study, the children have received standard
urotherapy as defined by the ICCS extended with visual
biofeedback by uroflowmetry and EMG electrodes and/or
retraining of the pelvic floor. If needed an additional treatment
with anticholinergics was started to treat urge-related
symptoms. The content of extended urotherapy was similar,
despite every child need his or her own stepwise approach. The
role of pharmacological therapy can be considered as ancillary
in the management of DV.3,5 A standard protocol for
urotherapy following a stepwise approach and uniform
reporting of outcomes would be helpful in current clinical
practice and facilitate comparison between studies.
One of the strengths of this study is the prospective inclusion
of all eligible children and the use of a standard measure to
evaluate the responsiveness.12 Children were recruited in
different hospital settings and received different types of
urotherapy, which makes the results of this study more
generalizable for current clinical practice. However, the
different approaches of urotherapy could possibly give some
bias on the outcome.Limitations include the absence of a control
group, the retrospective collection of LUTS data and the long
interval between finishing urotherapy and completing the last
questionnaires, which may have confounded the results.
5 | CONCLUSION
In contrast to the VSDESS, the PinQ is a responsiveness
questionnaire. The PinQ is able to detect clinically important
changes over time when treatment is given and can be used
initially, during follow up and after treatment to evaluate the
continence-specific quality of life in children with DV. We
support the use of the VSSDES questionnaire in addition to the
current diagnostics (voiding diary and uroflowmetry with
pelvic floor EMG) for the diagnosis of DV. Urotherapy with
visual biofeedback by uroflowmetry and EMG electrodes and/
or retraining of the pelvic floor showed to be a successful
treatment for children with DV, also for those who had
received previous unsuccessful treatment.
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